The marcus evans 15th Edition Next Generation Biotherapeutics Formulation, Process Development & Delivery Forum conference taking place in Cologne, Germany on 25-27 September, 2024 will explore new innovation and challenges in protein formulation for novel modalities targeting stability, high concentration, aggregation, and immunogenicity, impacting drugs like monoclonal antibodies, biospecifics, peptides, ADCs, AAV, and DNA/RNA-based therapies.

We’ll discuss the design, scale up and CMC strategies using predictive, AI/ML tools to optimise formulation and delivery within complex interactions, improving lab efficiency through automation and mitigate risks and predictions.

We’ll look at end to end process optimisation to maintain quality of product, while enhancing stability during delivery. We’ll consider as well new targeted approach linked to drug device improvement to bring an even more efficient and robust drug to the patient.

Topics covered include:

• Developing new biotherapeutics modalities and assure the robustness and quality in their formulation
• Unlocking the Potential of Polysorbate Alternatives – Insights into Surfactant’s Structure-Function relationship
• Leveraging Automation to Accelerate Drug Product Development
• Freeze-Drying technologies for complex and novel modalities biologics
• End to end LNP development to support mRNA delivery
• Scaling up Complex Biologics from the Lab to GMP and commercial Levels

Best Practices and Case Studies from:

• Joël Richard, PhD, Chief Development Officer, Enterome
• Joachim Schuster, Group Head, Lonza
• Stéphanie Greco, Head of laboratory in Pharmaceutical Engineering, Sanofi
• Maximilian Wittmann, Senior Scientist, Boehringer Ingelheim
• Sebastian Brosig, Principal Scientist, Drug Product Project Leader, Novartis
• Michelle Pascale Zöller, Senior Scientist, Merck

For more information use the Request Information button below or visit: www.marcusevans.com